Pure Global
NCT06269211

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression: a Prospective, Open-label, Multicenter, Single-arm Phase II Clinical Study
Ruijin Hospital·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carcinoma, Non-Small-Cell Lung
Drug/Device/Intervention
Toripalimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ruijin Hospital
Location
Guangzhou,Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Mar 30, 2024
End date
Jan 31, 2030
Enrollment
29 participants
Primary outcome

Major Pathological Response (MPR)

Summary

The study is a prospective, open label, multicenter, single arm Phase II clinical trial,
 aiming to explore the use of neoadjuvant Toripalimab for clinically stage II-IIIB NSCLC
 patients with EGFR mutations and PD-L1 positive expression, providing a novel perspective for
 further improving the prognosis of NSCLC patients. This study will provide valuable
 information for further clinical trials of neoadjuvant Toripalimab and other immune
 checkpoint inhibitors in NSCLC patients with EGFR mutations and PD-L1 positive expression.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06269211
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06269211 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ruijin Hospital and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 29 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.